Evidence for immunologic mechanisms in human vitiligo: patients' sera induce damage to human melanocytes in vitro by complement-mediated damage and antibody-dependent cellular cytotoxicity. 1988

D A Norris, and R M Kissinger, and G M Naughton, and J C Bystryn
Department of Dermatology, University of Colorado School of Medicine, Denver 80262.

Human vitiligo is a common depigmenting disorder that is often associated with polyendocrinopathies. The etiology of vitiligo is unknown although there is indirect evidence of a strong association between antimelanocyte antibodies in animal and human vitiligo. We report direct evidence that vitiligo patients' sera containing antimelanocyte antibodies can lyse cultured human melanocytes by both complement activation and antibody-dependent cellular cytotoxicity (ADCC). Melanocyte cytotoxicity was measured using an ethidium bromide/acridine orange viability assay, after 4 and 16 h incubation with sera from vitiligo patients and from normal controls. Significant melanocyte cytotoxicity was seen with vitiligo patients' sera as an antibody source with both complement-mediated cytotoxicity (p less than 0.01) and ADCC (p less than 0.05) as effector mechanisms. Nine of 11 vitiligo patients' sera produced cytotoxicity by complement-mediated lysis or ADCC. No cytotoxicity was seen using fibroblast targets and vitiligo patients' sera. The lysis of human melanocytes by vitiligo patients' sera by two different effector mechanisms provides direct support for the autoimmune hypothesis of human vitiligo.

UI MeSH Term Description Entries
D008544 Melanocytes Mammalian pigment cells that produce MELANINS, pigments found mainly in the EPIDERMIS, but also in the eyes and the hair, by a process called melanogenesis. Coloration can be altered by the number of melanocytes or the amount of pigment produced and stored in the organelles called MELANOSOMES. The large non-mammalian melanin-containing cells are called MELANOPHORES. Melanocyte
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D003165 Complement System Proteins Serum glycoproteins participating in the host defense mechanism of COMPLEMENT ACTIVATION that creates the COMPLEMENT MEMBRANE ATTACK COMPLEX. Included are glycoproteins in the various pathways of complement activation (CLASSICAL COMPLEMENT PATHWAY; ALTERNATIVE COMPLEMENT PATHWAY; and LECTIN COMPLEMENT PATHWAY). Complement Proteins,Complement,Complement Protein,Hemolytic Complement,Complement, Hemolytic,Protein, Complement,Proteins, Complement,Proteins, Complement System
D005347 Fibroblasts Connective tissue cells which secrete an extracellular matrix rich in collagen and other macromolecules. Fibroblast
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000920 Antibody-Dependent Cell Cytotoxicity The phenomenon of antibody-mediated target cell destruction by non-sensitized effector cells. The identity of the target cell varies, but it must possess surface IMMUNOGLOBULIN G whose Fc portion is intact. The effector cell is a "killer" cell possessing Fc receptors. It may be a lymphocyte lacking conventional B- or T-cell markers, or a monocyte, macrophage, or polynuclear leukocyte, depending on the identity of the target cell. The reaction is complement-independent. ADCC,Cytotoxicity, Antibody-Dependent Cell,Cell Cytoxicity, Antibody-Dependent,Antibody Dependent Cell Cytotoxicity,Antibody-Dependent Cell Cytotoxicities,Antibody-Dependent Cell Cytoxicities,Antibody-Dependent Cell Cytoxicity,Cell Cytotoxicities, Antibody-Dependent,Cell Cytotoxicity, Antibody-Dependent,Cell Cytoxicities, Antibody-Dependent,Cell Cytoxicity, Antibody Dependent,Cytotoxicities, Antibody-Dependent Cell,Cytotoxicity, Antibody Dependent Cell,Cytoxicities, Antibody-Dependent Cell,Cytoxicity, Antibody-Dependent Cell
D001323 Autoantibodies Antibodies that react with self-antigens (AUTOANTIGENS) of the organism that produced them. Autoantibody
D001327 Autoimmune Diseases Disorders that are characterized by the production of antibodies that react with host tissues or immune effector cells that are autoreactive to endogenous peptides. Autoimmune Disease,Disease, Autoimmune,Diseases, Autoimmune
D014820 Vitiligo A disorder consisting of areas of macular depigmentation, commonly on extensor aspects of extremities, on the face or neck, and in skin folds. Age of onset is often in young adulthood and the condition tends to progress gradually with lesions enlarging and extending until a quiescent state is reached.

Related Publications

D A Norris, and R M Kissinger, and G M Naughton, and J C Bystryn
January 2019, Journal of immunology research,
D A Norris, and R M Kissinger, and G M Naughton, and J C Bystryn
November 1979, Journal of clinical & laboratory immunology,
D A Norris, and R M Kissinger, and G M Naughton, and J C Bystryn
February 1990, Journal of clinical & laboratory immunology,
D A Norris, and R M Kissinger, and G M Naughton, and J C Bystryn
January 1977, Acta medica Academiae Scientiarum Hungaricae,
D A Norris, and R M Kissinger, and G M Naughton, and J C Bystryn
August 1991, Journal of neuroimmunology,
D A Norris, and R M Kissinger, and G M Naughton, and J C Bystryn
September 1994, Acta dermato-venereologica,
D A Norris, and R M Kissinger, and G M Naughton, and J C Bystryn
May 1977, Journal of the National Cancer Institute,
D A Norris, and R M Kissinger, and G M Naughton, and J C Bystryn
September 1995, The Journal of clinical investigation,
D A Norris, and R M Kissinger, and G M Naughton, and J C Bystryn
January 1991, Schweizer Archiv fur Neurologie und Psychiatrie (Zurich, Switzerland : 1985),
D A Norris, and R M Kissinger, and G M Naughton, and J C Bystryn
November 1974, Clinical immunology and immunopathology,
Copied contents to your clipboard!